Trends in incidence and survival in anal adenocarcinoma: A SEER study of racial and age disparities.

S Supriya Peshin (5Ballad Health, Johnson City, United States) S Shivani Modi (1Jefferson Einstein Medical Hospital, Philadelphia, United States) A Adit Dharia (13HCA Florida Oak Hospital, High Point, United States) R Rabia Iqbal (Dow Medical College, DUHS, Karachi, Pakistan) J Junaid Anwar (3MD ANDERSON CANCER CENTER, Houston, United States) R Rahul Borra (HCA Healthcare/USF Morsani College of Medicine Oak Hill Hospital, Brooksville, FL) N Nagaishwarya Moka (Middlesboro ARH Hospital, Middlesboro, KY)

Abstract

1 Background: Anal adenocarcinoma, a rare but increasingly diagnosed malignancy, has demonstrated rising incidence rates, warranting a deeper analysis of its epidemiology and outcomes across demographic factors like race and age. Methods: A retrospective analysis of data from SEER database (2000-2020) was conducted. Incidence rates per 100,000 individuals and 5-year survival outcomes were compared across racial groups (White, Black, Asian, Hispanic) and age categories (≤50 years, 51-70 years, >70 years). Additionally, trends were analyzed across two decades: 2000-2010 and 2010-2020. This study investigates epidemiological trends of anal adenocarcinoma, focusing on variations in incidence and survival outcomes by race and age, with specific comparisons between the periods 2000-2010 and 2010-2020. Results: Incidence of anal adenocarcinoma increased from 0.7 per 100,000 in 2000 to 1.6 per 100,000 in 2020. From 2000 to 2010, incidence increased rose 0.7 to 1.0 per 100,000, and from 2010 to 2020, it rose from 1.0 to 1.6 per 100,000. Rates were highest among Black individuals, increasing from 1.5 per 100,000 (2000-2010) to 2.3 (2010-2020), followed by White (1.2 to 1.5), Hispanic (0.8 to 1.0), and Asian populations (0.3 to 0.5). Age-related outcomes showed that in 2000-2010, patients aged ≤50 years had a 5-year survival rate of 75% versus 55% in age 51-70 versus 35% for >70 years. In 2010-2020, these rates dropped to 70%, 50%, and 30% in respective age groups. Racial disparities in survival were evident: Black patients had a 5-year survival rate of 40% (2000-2010) and 35% (2010-2020), significantly lower than White patients, who had rates of 65% (2000-2010) and 60% (2010-2020). Conclusions: The incidence of anal adenocarcinoma has steadily increased from 2000 to 2020, particularly among the Black population, while survival rates have declined. Additionally, survival rates are lower in individuals older than 70 years. Highlighting disparities in incidence and outcomes, further research is essential to uncover the underlying causes and develop targeted interventions to mitigate risks and improve patient outcomes. Keywords: anal adenocarcinoma, epidemiology, race, age, survival rates, disparities. This table summarizes the key trends in anal adenocarcinoma incidence and survival by race and age over the two decades from 2000 to 2020. The increases in incidence, particularly among Black individuals, and the worsening survival rates, especially in older and Black populations, are notable findings from the study. Category 2000-2010 2010-2020 Change (2000-2020) Incidence per 100,000 (Overall) 0.7 → 1.0 1.0 → 1.6 +0.9 Incidence by Race - White 1.2 → 1.5 1.5 → 1.5 +0.3 - Black 1.5 → 2.3 2.3 → 2.3 +0.8 - Hispanic 0.8 → 1.0 1.0 → 1.0 +0.2 - Asian 0.3 → 0.5 0.5 → 0.5 +0.2 5-Year Survival by Age - ≤50 years 75% 70% -5% - 51-70 years 55% 50% -5% - >70 years 35% 30% -5% 5-Year Survival by Race - White 65% 60% -5% - Black 40% 35% -5%

Article Details

Volume / Issue Vol. 43, Issue 4_suppl
Published February 01, 2025
Pages 1-1
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (7)

S

Supriya Peshin

5Ballad Health, Johnson City, United States

S

Shivani Modi

1Jefferson Einstein Medical Hospital, Philadelphia, United States

A

Adit Dharia

13HCA Florida Oak Hospital, High Point, United States

R

Rabia Iqbal

Dow Medical College, DUHS, Karachi, Pakistan

J

Junaid Anwar

3MD ANDERSON CANCER CENTER, Houston, United States

R

Rahul Borra

HCA Healthcare/USF Morsani College of Medicine Oak Hill Hospital, Brooksville, FL

N

Nagaishwarya Moka

Middlesboro ARH Hospital, Middlesboro, KY